◈ Nootpedia
Compact view
Research pass: medium Compound OPTIONAL-ADD MEDIUM

N-Acetyl-L-Tyrosine

Extended Research
◈ Extended Research ◈

Our depth — beyond the mirror

Deeper analysis, verdict reasoning, and per-archetype recommendations from our research team.

▸ Our verdict OPTIONAL-ADD MEDIUM

Marketing claims of superior bioavailability are largely refuted by pharmacokinetic data showing low systemic tyrosine yield; plain L-tyrosine is cheaper and better-evidenced. Keep as minor option only if GI tolerance to L-tyrosine is poor.

Research pass: medium
▸ Decision matrix by user profile Per-archetype
  • Dylan20-30, brain-priority, high cognitive workload (Dylan-archetype)
    OPTIONAL-ADD

    low — only if L-tyrosine causes GI issues; otherwise prefer l-tyrosine.md.

  • 30-50, executive maintenance
    OPTIONAL

    same caveat.

  • 50+, mild cognitive decline
    OPTIONAL

    minor.

  • Anxiety-prone
    NEUTRAL

    no anxiolytic, may exacerbate if stacked with stims.

  • High athletic load, tested status
    OPTIONAL

    pre-training PRN.

  • Sleep-disordered
    SKIP

    if dosed PM.

  • Recovery-focused
    N

    not a recovery agent.

  • Strength/anabolic-focused
    N
▸ Subjective experience (deep)
  • Reported effects mirror L-tyrosine but reportedly milder: subtle alertness, mild stress buffer under cognitive load.
  • Many users notice nothing at typical 300-500 mg doses (matches PK data — too little plasma tyrosine).
  • Some report "cleaner" feel than L-tyrosine — likely placebo or solubility comfort.
▸ Tolerance + cycling deep dive
  • Tolerance: minimal at typical doses.
  • Cycle: PRN; no daily-use case strong enough to justify cycling discussion.
▸ Stacking deep dive

Synergistic with

  • caffeine / modafinil: theoretical catecholamine substrate support — but L-tyrosine does this better.
  • alcar: mild dopaminergic stack.

Avoid stacking with

  • MAOI class drugs (rasagiline, selegiline): theoretical hypertensive risk if catecholamine pool is acutely loaded — moot at low NALT doses but worth noting.

Neutral / safe co-administration

  • V4 stack: no interactions of concern.
▸ Drug interactions deep dive
  • Levodopa: competes for the same large neutral amino acid (LNAA) transporter at the BBB; theoretical absorption interference.
  • Thyroid hormone: tyrosine is a thyroid hormone precursor — clinically irrelevant at supplement doses.
▸ Pharmacogenomics
  • COMT polymorphisms (Val158Met) modulate dopamine clearance; high-COMT (Val/Val) may benefit more from precursor loading; low-COMT (Met/Met) may be more sensitive to overload.
  • DBH variants affect norepinephrine synthesis from dopamine.
  • Both apply equally to L-tyrosine and (theoretically) to NALT — not a NALT-specific consideration.
▸ Sourcing deep dive
Path Vendor Cost Reliability Notes
OTC capsules Nutricost / Double Wood / NOW (iHerb/Amazon) $15-25 / 90-120 caps high Often 350-500 mg per cap
Bulk powder BulkSupplements $20-30 / 250 g high Better $/g than caps
In nootropic blends Many "focus" stacks varies medium Often underdosed
▸ Biomarkers to track (deep)
  • Baseline: Subjective alertness/focus baseline.
  • During use: Self-reported cognitive output vs L-tyrosine head-to-head.
  • Post-cycle: N/A.
▸ Controversies / open debates Live debate
  • "NALT is more bioavailable than L-tyrosine" — false per PK data; this is the central marketing claim and it's wrong.
  • Some vendors counter with anecdotal blind tests claiming equivalence; high-quality crossover RCTs are absent.
  • Some argue acetylated form is gentler on GI for sensitive users — plausible but unrigorous.
▸ Verdict change log
  • 2026-05-06 — Initial verdict: OPTIONAL-ADD low. Cheaper and better-evidenced alternative (L-tyrosine) makes NALT a niche pick.
▸ Open questions / gaps Open
  • A modern crossover PK + subjective trial comparing equimolar L-tyrosine vs NALT in healthy adults under cognitive stress would settle the debate.
  • Whether tissue-specific deacetylation (e.g., in brain) bypasses the renal excretion problem — unclear.
  • Long-term renal load of chronic high-dose NALT — under-studied.
▸ Sources (full, with our context)
Back to compact view